Drug intelligence / Profile preview

LFB101

Development stage: Preclinical
Lead developer: Leapfrog Bio
Modality: Small Molecules

Overview

LFB101 is a small molecule drug candidate under development by Leapfrog Bio for the treatment of neoplasms (cancers). It is part of Leapfrog Bio's pipeline of precision oncology therapeutics identified using their Precision PGx Platform. As of May 2025, LFB101 remains in preclinical development and has not yet entered clinical trials. The specific molecular target(s) and mechanism(s) of action have not been publicly disclosed. The compound is being developed to address genetically defined cancers with high unmet medical need[1][3].

Beyond the preview

Go deeper on LFB101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LFB101.

Explore the full profile